Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 6/20 | 0.67 |
| ▸ | MMP9 | P14780 | 6/20 | 0.67 |
| ▸ | MMP13 | P45452 | 6/20 | 0.67 |
| ▸ | MMP2 | P08253 | 5/20 | 0.67 |
| ▸ | MMP3 | P08254 | 5/20 | 0.67 |
| ▸ | MMP7 | P09237 | 5/20 | 0.67 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.61 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.59 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.59 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1770811 | 1.00 | MMP1 (0.67) | MMP1MMP9MMP13MMP2MMP3 | |
| SCHEMBL14025842 | 0.91 | ADAM17 (0.60) | MMP1MMP9MMP13MMP2MMP3 | |
| SCHEMBL4925808 | 0.91 | ADAM17 (0.60) | MMP1MMP9MMP13MMP2MMP3 | |
| SCHEMBL1832585 | 0.88 | MMP13 (0.59) | MMP1MMP9MMP13MMP2MMP3 | |
| SCHEMBL6979084 | 0.86 | SLC1A3 (0.73) | MMP1MMP9MMP13MMP2MMP3 | |
| SCHEMBL8529829 | 0.86 | SLC1A3 (0.73) | MMP1MMP9MMP13MMP2MMP3 | |
| SCHEMBL7405654 | 0.85 | SLC1A3 (0.60) | MMP1MMP9MMP13MMP2MMP3 | |
| SCHEMBL1828557 | 0.85 | MMP13 (0.56) | MMP1MMP9MMP13MMP2MMP3 | |
| SCHEMBL7380443 | 0.83 | MMP13 (0.77) | MMP1MMP9MMP13MMP2MMP3 | |
| SCHEMBL7380440 | 0.83 | MMP13 (0.77) | MMP1MMP9MMP13MMP2MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841291-B2 | Selective hydroxamic acid based MMP-12 and MMP-13 inhibitors | NOVARTIS AG (CH) | 2014-09-23 | — | — | US | disclosed |
| US-20140031399-A1 | SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS | NOVARTIS AG (CH) | 2014-01-30 | — | — | US | disclosed |
| US-20110112076-A1 | SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS | NOVARTIS AG (CH) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112076-A1 | SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS | MMP13, MMP11, MMP14 | MMP1 16/4885MMP9 10/4885MMP13 1/4885 |
| US-20140031399-A1 | SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS | MMP13, MMP11, MMP14 | MMP1 16/4885MMP9 9/4885MMP13 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.